University of Maryland Study

Medical & Clinical

Medical researchers and clinicians across the University System of Maryland are rapidly responding to improve diagnosis and treatment of patients who have been affected by COVID-19.



With funding from the State of Maryland, the School of Medicine has launched a large-scale COVID Testing Initiative to rapidly increase the state’s testing capabilities, with the goal of running 20,000 tests per day.
Researchers at the University of Maryland School of Medicine became the first in the U.S. to begin testing experimental COVID-19 vaccine candidates developed by Pfizer and BioNTech. The research, funded by Pfizer Inc., will study the safety, efficacy, and dosing of an experimental mRNA -based vaccine.
Through a national study sponsored by the National Institutes of Health, School of Medicine researchers are participating in a test to evaluate the effectiveness and safety of the antiviral drug remdesivir as a treatment for COVID-19-positive adult patients with pneumonia.

Department of Cell Biology & Molecular Genetics

University of Maryland, College Park

UMCP Logo

Researchers are helping to evaluate and develop new drugs to treat the novel coronavirus by performing molecular and genetic characterization and utilizing a physiologically-relevant model of human airway epithelium.

Department of Chemistry and Biochemistry

University of Maryland, Baltimore County

UMBC Logo

UMBC Professor Katherine Seley-Radtke is the principal investigator on a study to evaluate flexible nucleoside analogues with potent activity against epidemic and endemic human coronaviruses and obtaining critical data needed to move these potent compounds toward clinical trials.

University of Maryland School of Medicine

University of Maryland, Baltimore

UMB Logo

Researchers at the University of Maryland School of Medicine have begun testing the effectiveness of hydroxychloroquine as a therapy to prevent infection and symptoms in individuals who have been exposed to COVID-19-positive individuals. The trial is significant because it focuses on preventing rather than treating COVID-19.

UM Ventures

University of Maryland, Baltimore

UMB Logo

Gen1E Lifesciences has spent the last two years developing a therapeutic drug treatment for acute respiratory distress syndrome (ARDS), which is now the leading cause of death as a result of COVID-19. The company acquired an exclusive, worldwide and all-fields license to UMB's specific and function selective p38a kinase inhibitor program.

IES Life Sciences, Inc.

University of Maryland Eastern Shore

UMES Logo

Robert Figliozzi, research and development director at IES Life Sciences and University of Maryland Eastern Shore (UMES) doctoral candidate, manages collaborative research between IES, UMES and the USM. He is IES’ lead scientist in developing a test to detect COVID-19 infection in pre-symptomatic individuals, and measure the severity of the infection and the risk of experiencing a fatal cytokine storm.

School of Medicine (UMB) & Department of Chemical, Biochemical & Environmental Engineering (UMBC)

University of Maryland, Baltimore
University of Maryland, Baltimore County

UMB Logo

UMBC Logo

Scientists developed an experimental diagnostic test for COVID-19 that can visually detect the presence of the virus in 10 minutes. It uses a simple assay containing plasmonic gold nanoparticles to detect a color change when the virus is present. The test does not require the use of any advanced laboratory techniques for analysis.

School of Medicine

University of Maryland, Baltimore

UMB Logo

Researchers at the University of Maryland School of Medicine (UMSOM) have begun testing an experimental stem cell therapy developed by Mesoblast Limited to treat hospitalized COVID-19 patients with moderate to severe acute respiratory distress syndrome (ARDS) who are on ventilators to help them breathe.

Department of Biology

University of Maryland, College Park

UMCP Logo

Professor Michael Cummings, director of the Center for Bioinformatics and Computational Biology, is the principal investigator on a National Science Foundation-funded study focused on developing new strategies for analyzing genomic data from SARS-CoV-2. The study seeks to accelerate the analyses of SARS-CoV-2 genomic data needed by scientists and public health officials.

Institute of Human Virology
School of Medicine

University of Maryland, Baltimore

UMB Logo

The Center for International Health, Education and Biosecurity (Ciheb) at the University of Maryland School of Medicine’s Institute of Human Virology was awarded $4 million from the U.S. Centers for Disease Control and Prevention to support COVID-19 response activities in Botswana, Nigeria, Malawi, and Mozambique.

Department of Cell Biology and Molecular Genetics

University of Maryland, College Park

UMCP Logo

Assistant Professor Margaret Scull and Professor Jeffrey DeStefano from the University of Maryland’s Department of Cell Biology and Molecular Genetics have teamed up to develop an aptamer (small piece of nucleic acid that binds tightly to target proteins) with the potential to block COVID-19 infections. Scull’s lab is developing a complex cell model of the human airway, which will be used to test several different aptamers developed by DeStefano.

School of Medicine

University of Maryland, Baltimore

UMB Logo

Researchers evaluated several human antibodies to determine the most potent combination to be mixed and used as a promising anti-viral therapy against the virus COVID-19. Matthew Frieman, PhD, Associate Professor of Microbiology and Immunology, and his team identified a cocktail of two antibodies that is now being tested in a new clinical trial to determine whether the therapy can improve the outcomes of COVID-19 patients.
Professor Vonnie Shields has contributed to an international survey of COVID-19 patients designed to help prioritize the limited supply of testing materials for the disease. Working with the newly formed Global Consortium for Chemosensory Research, Dr. Shields has analyzed data related to COVID patients’ smell and taste and chemesthetic sensations.
Connect and Collaborate with
USM Experts and Institutions

CONNECT & COLLABORATE

USM experts seek opportunities to collaborate on solutions to the COVID-19 crisis. Now more than ever, partnership is critical.
To make a connection, use the contact form or email covidsolutions@usmd.edu.

Complete Form